SOUTH EASTON, Mass., Oct 08, 2008 /PRNewswire-FirstCall via COMTEX/ -- Pressure BioSciences, Inc. (PBIO) today provided an update on various corporate activities, including the presentation of favorable data generated by scientists at Amgen, Inc. on the Company's pressure cycling technology ("PCT"), the scheduled presentation by Dr. Paul Pevsner of the NYU School of Medicine on the use of PCT in identifying potential protein biomarkers in colon cancer samples, and guidance relative to forecasted Q32008 and FY2008 sales of the Company's Barocycler instruments.
1) Amgen Presentation: data were presented by scientists from Amgen at the 35th meeting of the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS) comparing PCT to their standard overnight procedure and the popular CEM, Inc. microwave-assisted technique for the digestion of a therapeutic monoclonal antibody. Amgen scientists reported that, "Pressure cycling was shown to be most effective at achieving complete digestion in a short time, without unintended perturbation of the molecule. Microwave digestion did not achieve complete digestion and induced oxidation of methionine residues." The authors concluded that, "PCT represents an increase in throughput and efficiency of at least 20-fold over the current conditions ... pressure cycling provided the most effective method for digesting monoclonal antibodies."
2) Dr. Paul Pevsner Presentation: Dr. Pevsner, Associate Professor of Pharmacology at the NYU School of Medicine, is scheduled to speak at the "Discovery2Diagnostics" Conference (San Diego, CA) on Monday, October 20th. Dr. Pevsner's talk, entitled "MALDI Imaging and Mass Spectrometry Identification of Colorectal Cancer Biomarkers", will include a discussion on the advantages of PCT versus other sample preparation methods available today. Dr. Pevsner is also expected to present data on the discovery of several proteins that he and his colleagues have found in colon cancer samples using PCT that have not been previously found in similar samples using other sample preparation techniques.
3) Guidance on Barocycler Sales: on August 14th, the Company announced that it expected to install at least fourteen (14) PCT Sample Preparation Systems during Q32008. The Company is pleased to announce that it has installed 17 PCT Systems, as compared to 7 in the second quarter of 2008. Furthermore, the Company expects to meet or exceed its previously announced full year guidance of 40 installations.
Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: "The continued publications and presentations from early adopters of PCT is helping us tremendously in our commercialization efforts. We attribute a significant portion of our recent commercial success to testimonials like the ones highlighted above, that herald the merits of pressure cycling technology in various applications of life sciences, as well as the advantages of PCT over other sample preparation methods available today. We would like to congratulate our customers and collaborators for their important research studies and for their continued support of PCT."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling, platform technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, and protein purification.
Forward-Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the use of the PCT SPS by the Brooklyn Hospital Center and the NYU School of Medicine, the results of their studies having been presented at the Annual Scientific Meeting of the American College of Gastroenterology. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that other laboratories may be unable to duplicate the results generated by Dr. Momeni and her colleagues; the possibility that the data generated may not be beneficial in the development of new therapeutics and diagnostics for colon cancer; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
CONTACT:
Pressure BioSciences, Inc.
Investor Contacts:
Richard T. Schumacher, President & CEO
Edward H. Myles, Sr. Vice President of Finance & CFO
(508) 580-1818